Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tarlatamab for Patients With Previously Treated Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma

NCT06816394 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT06816394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06816394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tarlatamab for Patients With Previously Treated Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma
Lead sponsor
National Taiwan University Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
January 1, 2026
Completion date
April 30, 2029
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extrapulmonary small cell carcinoma and neuroendocrine carcinoma